|
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00334646 |
This study is designed to evaluate the potential pharmacokinetic interaction between oral GW679769 and IV (intravenous) cyclophosphamide when administered to cancer patients.
Condition | Intervention | Phase |
Cancer |
Drug: Oral GW679769 Drug: IV Cyclophosphamide 500-700mg/m2 |
Phase I |
MedlinePlus related topics: | Cancer Nausea and Vomiting |
ChemIDplus related topics: | Cyclophosphamide GW679769 |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Crossover Assignment, Pharmacokinetics Study |
Official Title: | An Open Label, Repeat Dose, Randomized, Two Period Crossover Study to Investigate the Potential Pharmacokinetic Interactions Between Oral GW679769 and Intravenous Cyclophosphamide in Cancer Patients |
Estimated Enrollment: | 16 |
Study Start Date: | March 2005 |
Estimated Study Completion Date: | October 2008 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Arkansas | |||||
GSK Investigational Site | |||||
Hot Springs, Arkansas, United States, 71913 | |||||
United States, Delaware | |||||
GSK Investigational Site | |||||
Newark, Delaware, United States, 19713 | |||||
United States, New Jersey | |||||
GSK Investigational Site | |||||
Voorhees, New Jersey, United States, 08043 | |||||
United States, New Mexico | |||||
GSK Investigational Site | |||||
Albuquerque, New Mexico, United States, 87131 | |||||
United States, New York | |||||
GSK Investigational Site | |||||
Bronx, New York, United States, 10461 | |||||
New Zealand | |||||
GSK Investigational Site | |||||
Christchurch, New Zealand, 8001 | |||||
Sweden | |||||
GSK Investigational Site | |||||
LUND, Sweden, SE-221 85 | |||||
United Kingdom | |||||
GSK Investigational Site | |||||
London, United Kingdom, EC1A 7BE | |||||
United Kingdom, Hampshire | |||||
GSK Investigational Site | |||||
Southampton, Hampshire, United Kingdom, SO16 6YD |
GlaxoSmithKline |
Study Director: | GSK Clinical Trials, MD | GlaxoSmithKline |
Responsible Party: | GSK ( Study Director ) |
Study ID Numbers: | NKV103444 |
First Received: | June 6, 2006 |
Last Updated: | October 9, 2008 |
ClinicalTrials.gov Identifier: | NCT00334646 |
Health Authority: | United States: Food and Drug Administration; United Kingdom: Medicines and Healthcare Products Regulatory Agency; United States: Food and Drug Administration |
|
|
|
|